Pharma Focus Asia

GeminiBio Plans to Contruct New Liquid Manufacturing Facility

Introduction:

GeminiBio opens new cGMP bioprocess liquid manufacturing facility in California, USA. 

Features:

This new high-volume liquid production facility significantly increases cGMP bioprocess liquids production capacity.

This new manufacturing facility enables to supply speciality cGMP cell culture media, buffers, water for injection (WFI) and other process fluids in batches of up to 10,000 litres for biotech and life sciences customers.

With the increase of large-scale process fluid production to the existing small and medium-sized capabilities enables cGMP process fluid manufacturing in sizes from 10 litres to 10,000 litres. In addition to the current 500- and 1000-litre formulation tanks, the new facility will consist of one 5000-litre and two 10,000-litre stainless steel tanks.

The production of transformative biotherapies, consisting cell and gene therapies, needs a wide range of upstream and downstream process fluids. The advanced manufacturing capability will further allow to simplify and streamline customer manufacturing flows while improving supply reliability.

Specifications:

Name      GeminiBio
Type        New Construction

 

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference